Literature DB >> 16239638

Selling safety--lessons from muraglitazar.

James M Brophy.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16239638     DOI： 10.1001/jama.294.20.jed50074

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  5 in total

1.  The market in diabetes.

Authors:  Alexandra Hauber; Edwin A M Gale
Journal:  Diabetologia       Date:  2006-02       Impact factor: 10.122

2.  Unbalanced reporting of benefits and harms in abstracts on rofecoxib.

Authors:  Anders W Jørgensen; Karsten Juhl Jørgensen; Peter C Gøtzsche
Journal:  Eur J Clin Pharmacol       Date:  2010-02-17       Impact factor: 2.953

3.  Why we need easy access to all data from all clinical trials and how to accomplish it.

Authors:  Peter C Gøtzsche
Journal:  Trials       Date:  2011-11-23       Impact factor: 2.279

4.  Antidiabetic action of bezafibrate in a large observational database.

Authors:  James H Flory; Susan Ellenberg; Philippe O Szapary; Brian L Strom; Sean Hennessy
Journal:  Diabetes Care       Date:  2009-01-08       Impact factor: 17.152

5.  Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists.

Authors:  Martin B Oleksiewicz; Jennifer Southgate; Lars Iversen; Frederikke L Egerod
Journal:  PPAR Res       Date:  2009-01-28       Impact factor: 4.964
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.